Adiso Therapeutics

Its first comppund, ADS024 (SS-LBP), is currently being evaluated in a Phase 1b study for the prevention of recurrent CDI and a Phase 2 study in mild-to-moderate ulcerative colitis (UC). ADS051 is currently enrolling a Ph1b study in moderate-to-severe ulcerative colitis (UC). Adiso is also developing a novel dual inflammasome inhibitor in discovery phase which is being initially explored in respiratory inflammation, with multiple future therapeutic areas to pursue.